MYLAN-HYDROXYUREA CAPSULE

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

HYDROXYUREA

Tilgængelig fra:

MYLAN PHARMACEUTICALS ULC

ATC-kode:

L01XX05

INN (International Name):

HYDROXYCARBAMIDE

Dosering:

500MG

Lægemiddelform:

CAPSULE

Sammensætning:

HYDROXYUREA 500MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100

Recept type:

Prescription

Terapeutisk område:

ANTINEOPLASTIC AGENTS

Produkt oversigt:

Active ingredient group (AIG) number: 0113432001; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2009-07-02

Produktets egenskaber

_MYLAN-HYDROXYUREA (hydroxyurea capsules) _
_ _
_Page 1 of 27 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MYLAN-HYDROXYUREA
Hydroxyurea Capsules
Capsules, 500 mg, Oral
USP
Antineoplastic Agent
Mylan Pharmaceuticals ULC
Date of Initial Authorization:
85 Advance Road
October 17, 2000
Etobicoke, Ontario
M8Z 2S6
Date of Revision:
Canada
April 4, 2023
Submission Control Number: 268902
_MYLAN-HYDROXYUREA (hydroxyurea capsules) _
_ _
_Page 2 of 27 _
RECENT MAJOR LABEL CHANGES
1 Indications
04/2023
7 Warnings and Precautions, Carcinogenesis and Mutagenesis
04/2023
7 Warnings and Precautions, Hematologic
04/2023
7 Warnings and Precautions, Reproductive Health: Female and Male
Potential
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................................
2
TABLE OF CONTENTS
............................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1 INDICATIONS
.....................................................................................................................................
4
1.1 Pediatrics
............................................................................................................................................
4
1.2 Geriatrics
............................................................................................................................................
4
2 CONTRAINDICATIONS
.......................................................................................................................
4
4 DOSAGE AND ADMINISTRATION
.......................................................................................................
4
4.1 Dosing Considerations
................................................